Last reviewed · How we verify
Paclitaxel only
Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying.
Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from multiplying. Used for Adjuvant treatment of node-positive breast cancer, Adjuvant treatment of ovarian cancer, Adjuvant treatment of non-small cell lung cancer.
At a glance
| Generic name | Paclitaxel only |
|---|---|
| Sponsor | Tata Memorial Hospital |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel binds to tubulin, a protein that makes up microtubules in cells. By binding to tubulin, paclitaxel stabilizes microtubules and prevents them from disassembling, which is necessary for cell division. This prevents cancer cells from entering the mitotic phase and ultimately leads to cell death.
Approved indications
- Adjuvant treatment of node-positive breast cancer
- Adjuvant treatment of ovarian cancer
- Adjuvant treatment of non-small cell lung cancer
- Treatment of AIDS-related Kaposi's sarcoma
- Treatment of breast cancer
- Treatment of ovarian cancer
- Treatment of non-small cell lung cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Mucositis
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients (PHASE3)
- Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (PHASE1)
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |